Isomorphic Labs Raises $2.1 Billion for AI Drug Discovery

Isomorphic Labs announced that it has secured $2.1 billion in Series B financing to expand its artificial intelligence-powered drug discovery and development platform, marking one of the largest recent investment rounds in the rapidly growing AI healthcare sector.

The funding round was led by Thrive Capital and included participation from existing investors Alphabet and GV, along with new investors including MGX, Temasek, CapitalG, and the UK Sovereign AI Fund.

The company said the new capital will be used to accelerate development and deployment of its proprietary AI drug design engine, known as IsoDDE, while expanding its therapeutic pipeline toward clinical-stage programs. The funding will also support hiring initiatives across artificial intelligence, engineering, drug development, and clinical research operations.

Isomorphic Labs, founded as an AI-first pharmaceutical research company, focuses on using advanced machine learning systems to redesign how medicines are discovered and developed. The company aims to combine biological research with large-scale AI systems capable of rapidly identifying and optimizing potential drug candidates.

Demis Hassabis, Founder and Chief Executive Officer of Isomorphic Labs, described the investment as a strong endorsement of the company’s AI-first strategy for drug design and development. He said the organization has demonstrated that its scientific and engineering approach is fundamentally effective and is now focused on scaling the technology platform to its full capabilities.

Hassabis added that the financing will allow the company to further expand its AI-driven drug design engine with the long-term objective of addressing a broad range of diseases through advanced computational biology.

The company stated that its proprietary AI systems are already showing progress within internal research programs by helping identify viable drug candidates with significantly improved speed compared with traditional pharmaceutical development methods.

Max Jaderberg, President of Isomorphic Labs, said the company’s AI platform has achieved important milestones across multiple therapeutic programs. According to Jaderberg, the technology provides a repeatable framework for designing new medicines for a wide range of diseases, potentially transforming the future of drug discovery.

Investors participating in the financing round emphasized growing confidence in AI-driven pharmaceutical research. Ruth Porat, President and Chief Investment Officer of Alphabet and Google, said artificial intelligence presents a major opportunity in healthcare and noted that Isomorphic Labs has already made significant progress in accelerating drug discovery using AI technologies.

Joshua Kushner, Founder and CEO of Thrive Capital, said the company’s progress over the past year strengthened investor confidence in its ability to create a unified AI drug design platform capable of reshaping pharmaceutical innovation.

Krishna Yeshwant, Managing Partner at GV, described Isomorphic Labs as one of the leading organizations operating at the intersection of artificial intelligence and drug discovery. He said the company’s approach could help create medicines that are better understood earlier in development while expanding scientific possibilities in pharmaceutical research.

The financing highlights continued investor enthusiasm for AI-powered healthcare companies as the pharmaceutical industry increasingly adopts advanced computational tools to accelerate therapeutic development and reduce drug discovery timelines.